Prevalence and characteristics of psychotropic drug use in institutionalized children and adolescents with mild intellectual disability

Research in Developmental Disabilities

Volumn 34, Issue 10, 2013, Pages 3159-3167

  Scheifes, Arlette ^a,b   de Jong, Daniël ^a   Stolker, Joost Jan ^a,c   Nijman, Henk L I ^b,d   Egberts, Toine C G ^a,e   Heerdink, Eibert R ^a,e  

^a UTRECHT UNIVERSITY   (Netherlands)

^b Altrecht Institute for Mental Healthcare   (Netherlands)

^c Koerseigen Consultancy   (Netherlands)

^d RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Behavioral problems; Children and adolescents; Intellectual disability; Prevalence; Psychotropic drugs

Indexed keywords

ARIPIPRAZOLE; ATOMOXETINE; BENZODIAZEPINE; BUSPIRONE; DEXAMPHETAMINE; HALOPERIDOL; MELATONIN; METHYLPHENIDATE; OLANZAPINE; PIPAMPERONE; QUETIAPINE; RISPERIDONE;

ADOLESCENT; ADULT; AGE; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; AUTISM; AUTOMUTILATION; CHILD; CROSS-SECTIONAL STUDY; DEPRESSION; DISEASE SEVERITY; DRUG USE; EMOTIONAL ATTACHMENT; FEMALE; HUMAN; HYPERACTIVITY; INSTITUTIONALIZATION; INTELLECTUAL IMPAIRMENT; MALE; MEDICAL RECORD; MOOD DISORDER; NETHERLANDS; OPPOSITIONAL DEFIANT DISORDER; PHYSICAL ABUSE; PRESCHOOL CHILD; PRESCRIPTION; PREVALENCE; SCHOOL CHILD; SEX; SEXUAL BEHAVIOR; SUICIDAL BEHAVIOR; VERBAL HOSTILITY;

BEHAVIORAL PROBLEMS; CHILDREN AND ADOLESCENTS; INTELLECTUAL DISABILITY; PREVALENCE; PSYCHOTROPIC DRUGS;

ADOLESCENT; ADOLESCENT, INSTITUTIONALIZED; CHILD; CHILD BEHAVIOR DISORDERS; CHILD, INSTITUTIONALIZED; CROSS-SECTIONAL STUDIES; DRUG UTILIZATION; FEMALE; HUMANS; INTELLECTUAL DISABILITY; MALE; NETHERLANDS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PREVALENCE; PSYCHOTROPIC DRUGS; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; YOUNG ADULT;

EID: 84880834910     PISSN: 08914222     EISSN: 18733379     Source Type: Journal    
DOI: 10.1016/j.ridd.2013.06.009     Document Type: Article

References (40)

1. Aman M.G., Sarphare G., Burrow W.H. Psychotropic-drugs in group homes-Prevalence and relation to demographic psychiatric variables. American Journal on Mental Retardation 1995, 99(5):500-509.
2. Aman M.G., Buican B., Arnold L.E. Methylphenidate treatment in children with borderline IQ and mental retardation: Analysis of three aggregated studies. Journal of Child and Adolescent Psychopharmacology 2003, 13(1):29-40.
3. Bokszanska A., Martin G., Vanstraelen M., Holt G., Bouras N., Taylor D. Risperidone and olanzapine in adults with intellectual disability: A clinical naturalistic study. International Clinical Psychopharmacology 2003, 18(5):285-291.
4. Bramble D. Psychotropic drug prescribing in child and adolescent learning disability psychiatry. Journal of Psychopharmacology 2007, 21(5):486-491.
5. Cohen D., Raffin M., Canitano R., Bodeau N., Bonnot O., Perisse D., et al. Risperidone or aripiprazole in children and adolescents with autism and/or intellectual disability: A bayesian meta-analysis of efficacy and secondary effects. Research in Autism Spectrum Disorders 2013, 7(1):167-175.
6. Comer J.S., Chow C., Chan P.T., Cooper-Vince C., Wilson L.A.S. Psychosocial treatment efficacy for disruptive behavior problems in very young children: A meta-analytic examination. Journal of the American Academy of Child & Adolescent Psychiatry 2013, 52(1):26-36.
7. De Bildt A., Mulder E.J., Scheers T., Minderaa R.B., Tobi H. Pervasive developmental disorder, behavior problems, and psychotropic drug use in children and adolescents with mental retardation. Pediatrics 2006, 118(6):e1860-e1866.
8. De Kuijper G., Evenhuis H., Minderaa R.B., Hoekstra P.J. Effects of controlled discontinuation of long-term used antipsychotics for behavioural symptoms in individuals with intellectual disability. Journal of Intellectual Disability Research 2012, October. 10.1111/j.1365-2788.2012.01631.x.
9. Dekker M.C., Koot H.M. DSM-IV disorders in children with borderline to moderate intellectual disability. I: Prevalence and impact. Journal of the American Academy of Child and Adolescent Psychiatry 2003, 42(8):915-922.
10. Dekker M.C., Koot H.M., Van Der Ende J., Verhulst F.C. Emotional and behavioral problems in children and adolescents with and without intellectual disability. Journal of Child Psychology and Psychiatry 2002, 43(8):1087-1098.
11. Haegeman J., Duyck F. A retrospective evaluation of pipamperone (dipiperon) in the treatment of behavioural deviations in severely mentally handicapped. Acta Psychiatrica Belgica 1978, 78(2):392-398.
12. Handen B.L., Gilchrist R. Practitioner review: Psychopharmacology in children and adolescents with mental retardation. Journal of Child Psychology and Psychiatry 2006, 47(9):871-882.
13. Haw C., Stubbs J. A survey of off-label prescribing for inpatients with mild intellectual disability and mental illness. Journal of Intellectual Disability Research 2005, 49(11):858-864.
14. Holden B., Gitlesen J.P. Psychotropic medication in adults with mental retardation: Prevalence, and prescription practices. Research in Developmental Disabilities 2004, 25(6):509-521.
15. Kalverdijk L.J., Tobi H., Van Den Berg P.B., Buiskool J., Wagenaar L., Minderaa R.B., et al. Use of antipsychotic drugs among dutch youths between 1997 and 2005. Psychiatric Services 2008, 59(5):554-560.
16. Kiernan C., Reeves D., Alborz A. The use of anti-psychotic drugs with adults with learning disabilities and challenging behaviour. Journal of Intellectual Disability Research 1995, 39(4):263-274.
17. Klaassen A.A.G. Pipamperone and the treatment of impulsive aggressive behaviour. Tijdschrift Voor Psychiatrie 2008, 50(3):179-183.
18. Lakhan S.E., Hagger-Johnson G.E. The impact of prescribed psychotropics on youth. Clinical Practice and Epidemiology in Mental Health 2007, 3:21.
19. Matson J.L., Neal D. Psychotropic medication use for challenging behaviors in persons with intellectual disabilities: An overview. Research in Developmental Disabilities 2009, 30(3):572-586.
20. Olfson M., Blanco C., Liu L., Moreno C., Laje G. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Archives of General Psychiatry 2006, 63(6):679-685.
21. Olfson M., Marcus S.C., Weissman M.M., Jensen P.S. National trends in the use of psychotropic medications by children. Journal of the American Academy of Child and Adolescent Psychiatry 2002, 41(5):514-521.
22. Paton C., Flynn A., Shingleton-Smith A., Mcintyre S., Bhaumik S., Rasmussen J., et al. Nature and quality of antipsychotic prescribing practice in UK psychiatry of intellectual disability services. Journal of Intellectual Disability Research 2011, 55(7):665-674.
23. Posey D.J., Stigler K.A., Erickson C.A., McDougle C.J. Antipsychotics in the treatment of autism. Journal of Clinical Investigation 2008, 118(1):6-14.
24. Risperidon - kenniscentrum-kjp.nl. 2013, from http://www.kenniscentrum-kjp.nl/nl/Professionals/formularium/vervolgpagina_s/risperidon.html.
25. Scheifes A., Stolker J.J., Egberts A.C.G., Nijman H.L.I., Heerdink E.R. Representation of people with intellectual disabilities in randomised controlled trials on antipsychotic treatment for behavioural problems. Journal of Intellectual Disability Research 2011, 55(7):650-664.
26. Shireman T., Reichard A., Rigler S. Psychotropic medication use among kansas medicaid youths with disabilities. Journal of Child and Adolescent Psychopharmacology 2005, 15(1):107-115.
27. Simonoff E., Taylor E., Baird G., Bernard S., Chadwick O., Liang H., et al. Randomized controlled double-blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability. Journal of Child Psychology and Psychiatry 2013, 54(5):527-535.
28. Singh N.N., Ellis C.R., Wechsler H. Psychopharmacoepidemiology of mental retardation: 1966 to 1995. Journal of Child and Adolescent Psychopharmacology 1997, 7(4):255-266.
29. Stolker J.J., Heerdink E.R., Leufkens H.G.M., Clerkx M.G.M., Nolen W.A. Determinants of multiple psychotropic drug use in patients with mild intellectual disabilities or borderline intellectual functioning and psychiatric or behavioral disorders. General Hospital Psychiatry 2001, 23(6):345-349.
30. Stolker J.J., Koedoot P.J., Heerdink E.R., Leufkens H.G.M., Nolen W.A. Psychotropic drug use in intellectually disabled group-home residents with behavioural problems. Pharmacopsychiatry 2002, 35(1):19-23.
31. Tenneij N.H., Didden R., Stolker J.J., Koot H.M. Markers for aggression in inpatient treatment facilities for adults with mild to borderline intellectual disability. Research in Developmental Disabilities 2009, 30(6):1248-1257.
32. Tobi H., Scheers T., Netjes K., Mulder E., de Bildt A., Minderaa R. Drug utilisation by children and adolescents with mental retardation: A population study. European Journal of Clinical Pharmacology 2005, 61(4):297-302.
33. Tsiouris J.A., Kim S.Y., Brown W.T., Pettinger J., Cohen I.L. Prevalence of psychotropic drug use in adults with intellectual disability: Positive and negative findings from a large scale study. Journal of Autism and Developmental Disorders 2013, 43(3):719-731.
34. Unwin G.L., Deb S. Efficacy of atypical antipsychotic medication in the management of behaviour problems in children with intellectual disabilities and borderline intelligence: A systematic review. Research in Developmental Disabilities 2011, 32(6):2121-2133.
35. Van Daalen E., Buitelaar J.K. Prescription of psychotropic drugs by Dutch child and adolescent psychiatrists to children and adolescents with psychiatric disorders. Tijdschrift Voor Psychiatrie 1999, 41(1):3-13.
36. Van Hemert J.C. Pipamperone (dipiperon, R3345) in troublesome mental retardates: A double-blind placebo controlled cross-over study with long-term follow-up. Acta Psychiatrica Scandinavica 1975, 52(4):237-245.
37. Vitiello B., Correll C., van Zwieten-Boot B., Zuddas A., Parellada M., Arango C. Antipsychotics in children and adolescents: Increasing use, evidence for efficacy and safety concerns. European Neuropsychopharmacology 2009, 19(9):629-635.
38. Wallander J.L., Dekker M.C., Koot H.M. Psychopathology in children and adolescents with intellectual disability: Measurement, prevalence, course, and risk. International review of research in mental retardation 2003, Vol. 26:93-134. Academic Press, San Diego, CA.
39. WHOCC - ATC/DDD index. 2013, from http://www.whocc.no/atc_ddd_index/.
40. Zito J.M., Safer D.J., DosReis S., Gardner J.F., Magder L., Soeken K., et al. Psychotropic practice patterns for youth: A 10-year perspective. Archives of Pediatrics and Adolescent Medicine 2003, 157(1):17-25.